Roy Buchanan

Stock Analyst at JMP Securities

(1.56)
# 1765
Out of 5,441 analysts
78
Total ratings
Success rate
Average return
18 Stocks
Name Action PT Current % Upside Ratings Updated
ENTA Enanta Pharma
Maintains: Market Outperform
24 25
6.48 285.8% 15 Aug 12, 2025
DVAX Dynavax Technologies
Maintains: Market Outperform
31 32
10.47 205.64% 7 Aug 8, 2025
CDTX Cidara Therapeutics
Maintains: Market Outperform
59 66
61.9 6.62% 7 Aug 8, 2025
PYPD PolyPid
Maintains: Market Outperform
16 14
3.19 338.87% 2 Jun 17, 2025
CVAC CureVac
Reiterates: Market Outperform
10 10
5.42 84.5% 9 May 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
5 2
1.05 90.48% 9 May 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
18 18
1.45 1141.38% 3 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
n/a
n/a n/a 1 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
7 4
1.85 116.22% 3 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
23 14
0.84 1566.67% 1 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Outperform
33 33
69.02 -52.19% 1 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
24 7
0.84 733.33% 2 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 5 Oct 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
4 5
3.34 49.7% 5 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 3 Jul 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Outperform
443 448
638.76 -29.86% 2 Mar 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
14 16
10.06 59.05% 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Feb 16, 2023